Cochrane · systematic review · CD006739
Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus
Richter, B, Bandeira‐Echtler, E, Bergerhoff, K, et al. · Cochrane Database of Systematic Reviews · 2008 · Cochrane Library
Metabolic and Endocrine DisordersAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
10
No studies
4
Included studies
NR
No studies 4 · 28.6%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 10 · 71.4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Summary of findings: Sitagliptin
Population: type 2 diabetes mellitus
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Morbidity | no estimate extracted | NR | No studies |
Health‐related quality of life | no estimate extracted | NR | No studies |
Change in HbA1c from baseline to endpoint % ( | no estimate extracted | 11 studies · 6907 participants | High |
Change in HbA1c from baseline to endpoint ‐ Sitagliptin versus another single hypoglycaemic agent % ( | no estimate extracted | 2 studies · 592 participants | High |
Change in HbA1c from baseline to endpoint [%] ‐ Sitagliptin versus placebo % ( | no estimate extracted | 3 studies · 1103 participants | High |
Change in body weight from baseline to endpoint ‐ Sitagliptin versus placebo kg ( | no estimate extracted | 3 studies · 1109 participants | High |
Adverse events ‐ All‐cause infections ( | RR 1.29 [1.09, 1.52] | 8 studies · 3589 participants | High |
Summary of findings: Vildagliptin
Population: patients with type 2 diabetes mellitus
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Morbidity | no estimate extracted | NR | No studies |
Health‐related quality of life | no estimate extracted | NR | No studies |
Change in HbA1c from baseline to endpoint % ( | no estimate extracted | 14 studies · 6308 participants | High |
Change in HbA1c from baseline to endpoint ‐ Vildagliptin versus another single hypoglycaemic agent % ( | no estimate extracted | 3 studies · 1764 participants | High |
Change in HbA1c from baseline to endpoint ‐ Vildagliptin versus placebo % ( | no estimate extracted | 6 studies · 1139 participants | High |
Change in body weight from baseline to endpoint ‐ Vildagliptin versus placebo kg ( | no estimate extracted | 3 studies · 484 participants | High |
Adverse events ‐ All‐cause infections ( | RR 1.04 [0.87, 1.24] | 10 studies · 3573 participants | High |